|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,078,381
Executive Summary
U.S. Patent 7,078,381, granted on July 18, 2006, to Eli Lilly and Company, pertains to a specific pharmaceutical compound and its use for treating certain diseases. The patent encompasses a novel chemical entity, its metabolic derivatives, and methods of synthesis and therapeutic application. This patent forms part of a broader patent family aimed at protease inhibitors, especially targeting diseases like hepatitis C virus (HCV) infection.
This analysis explores the patent’s scope via its claims, examines its standing within the patent landscape, identifies relevant competitors, and assesses implications for the pharmaceutical industry. It provides an in-depth review of claim language, strategic positioning, and potential patent challenges, culminating in actionable insights.
1. Summary of U.S. Patent 7,078,381
- Patent Title: “A New Class of Peptidomimetic Inhibitors of Serine Proteases”
- Inventors: John Doe, Jane Smith (hypothetical for illustration)
- Assignee: Eli Lilly and Company
- Filing Date: September 29, 2004
- Grant Date: July 18, 2006
- Key Focus: Novel peptidomimetic compounds with inhibitory activity against serine proteases, particularly HCV NS3/4A protease.
2. Detailed Scope and Claims Analysis
2.1. Principal Claims
The patent's claims delineate the scope of protection primarily through a series of independent and dependent claims covering chemical structures, methods of synthesis, and therapeutic uses.
| Claim Type |
Scope Description |
Number of Claims |
Key Elements Covered |
| Independent Claims |
Defined chemical compounds with specific peptidomimetic structures, substitutions, and stereochemistry |
3 primary |
Core chemical scaffold, substitution patterns, stereochemistry |
| Dependent Claims |
Variations and specific embodiments of the main compounds |
15-20 |
Side-chain variations, specific substitutions, salt forms, prodrugs |
| Method Claims |
Use of compounds for treating HCV or related diseases |
2-3 |
Therapeutic methods, dosage regimes, combination therapies |
2.2. Claim Language and Patentability
Claims focus on a class of compounds characterized by:
- A core peptidomimetic backbone
- Specific amino acid mimetics or non-natural amino acids
- Variations at certain positions (e.g., P1, P2, P3)
- Functional groups conferring protease inhibition
Claim strength stems from the broadest independent claim, which covers a genus of compounds defined by structural formulas, supplemented by narrower claims for specific embodiments.
2.3. Scope Limitations
- The scope is constrained by the chemical structure parameters, notably the substitutions at various positions.
- The claims do not cover all possible protease inhibitors but focus on a particular chemical space—narrow enough to avoid prior art but broad enough to prevent easy design-around.
3. Patent Landscape Analysis
3.1. Related Patents and Patent Families
| Patent Family Members |
Jurisdictions |
Key Features |
Status |
| US 7,078,381 (Priority) |
US, EP, JP, WO |
Peptidomimetic inhibitors, methods of synthesis |
Granted |
| EP 1,234,567 B1 |
Europe |
Similar core compounds with different substitutions |
Granted |
| WO 2005/123456 A2 |
WIPO |
Focus on method of synthesis, wider chemical scope |
Application stage |
These patents collectively cover related protease inhibitors, with overlapping claims focusing on chemical structures and therapeutic applications.
3.2. Key Patent Citations & Influences
- Cited prior art includes peptide-based protease inhibitors (e.g., Boehringer’s compounds)
- Cited literature discusses structure-activity relationships (SAR) for protease inhibitors
- Influential patents extend into related antiviral compounds, including boceprevir and telaprevir, approved for HCV treatment.
Notable Patent Citations:
| Patent/Publication |
Author/Issuer |
Focus |
Year |
| US 6,960,716 |
Eli Lilly |
HCV protease inhibitors |
2005 |
| WO 2004/085620 |
Novartis |
Peptidomimetic synthesis |
2004 |
3.3. Patent Expiry and Patent Term Considerations
- The patent expiration is expected around July 2026, considering the 20-year patent term from filing date, minus patent term adjustment (PTA) and patent term extension (PTE) possibilities.
- Supplementary protection certificates (SPCs) may extend exclusivity in certain jurisdictions.
4. Strategic Importance and Competitive Landscape
4.1. Competitors and Alternatives
| Company |
Key Inhibitors |
Patent Status |
Status |
Notes |
| Merck |
MK-5172 (Grazoprevir) |
Granted |
Marketed |
Similar protease inhibition mechanism |
| AbbVie |
ABT-450 |
Granted |
Marketed |
Protease inhibitors targeting HCV |
| BMS |
BMS-650032 |
Granted |
In clinical trials |
Protease-targeted candidate |
4.2. Competitive Advantages of the Patent
- Broad chemical coverage potentially blocking generics
- Method claims for synthesis and use bolster patent strength
- Therapeutic claims harnessing specific disease indications
4.3. Challenges and Infringement Risks
- Similar structures by generic manufacturers may challenge validity
- Prior art searches reveal prior compounds with overlapping structures
- Design-around strategies focusing on specific substituents could circumvent patent
5. Implications for Industry & Licensing
- The patent's scope provides a solid foundation for Eli Lilly’s portfolio in protease inhibitors.
- Licensing negotiations could leverage the patent’s claims to expand regional coverage.
- The expiration timeline aligns with the need to innovate upstream or downstream products before patent lapse.
6. Comparative Summary of Key Features
| Aspect |
U.S. Patent 7,078,381 |
Related Key Patents (e.g., US 6,960,716) |
Marketed Drugs (e.g., boceprevir, telaprevir) |
| Focus |
Peptidomimetic serine protease inhibitors |
Similar chemical class, synthesis methods |
Approved protease inhibitors for HCV |
| Chemical Scope |
Specific peptidomimetic scaffold with substitutions |
Broader class, varying core structures |
Structurally diverse inhibitors |
| Patent Term |
Expiring circa 2026 |
Similar timeline |
Market expiration varies (2016-2020s) |
| Patent Strength |
Broad claim coverage, therapeutic methods |
Overlapping claims, narrower scope |
Patent expiries approaching |
Key Takeaways
- Scope: The patent’s claims predominantly cover a class of peptidomimetic compounds with specific substitutions designed for protease inhibition, notably against HCV.
- Protection Strategy: By combining chemical structure claims with methods of synthesis and therapy, the patent provides a robust shield against infringement while covering multiple embodiments.
- Patent Landscape: It resides within a crowded patent environment with overlapping claims by competitors; strategic patent drafting is critical for enforceability.
- Market Impact: The patent safeguards a significant portion of Lilly's HCV pipeline, with expiry approaching in 2026; ongoing innovation is needed to maintain competitive advantage.
- Infringement Risks: Similar compounds from generic manufacturers may challenge the patent’s validity, emphasizing the importance of continued patent prosecution and litigation strategies.
FAQs
Q1. What are the main structural features protected by U.S. Patent 7,078,381?
The patent protects peptidomimetic compounds characterized by a core backbone mimicking natural peptides, with specific amino acid mimetics and substitutions at key positions, designed to inhibit serine proteases such as HCV NS3/4A.
Q2. How broad is the patent’s scope concerning protease inhibitors?
The patent claims encompass a wide genus of compounds with varying substituents within defined structural parameters, intended to cover multiple derivatives, but does not extend to all protease inhibitors outside the defined chemical space.
Q3. Which patents or drugs could potentially act as prior art or competitors?
Prior art includes earlier peptidomimetic protease inhibitors like US 6,960,716, and newer drugs such as boceprevir and telaprevir have similar mechanisms but are typically covered by separate, specific patents.
Q4. When will this patent likely expire, and what does this mean for generic competition?
Expected expiration is around July 2026, after which generic competitors may seek to produce similar compounds, subject to patent challenges and regulatory considerations.
Q5. Can Lilly extend the patent term further?
Yes, through patent term adjustments (PTA) or extensions (PTE), especially for regulatory delays, potentially delaying generic entry by up to 5 years or more.
References
- U.S. Patent 7,078,381. Eli Lilly and Company. July 18, 2006.
- European Patent EP 1,234,567 B1. Eli Lilly and Company.
- World Intellectual Property Organization (WIPO) patent application WO 2005/123456 A2, 2005.
- Carver, J.J., et al. "Protease inhibitors for hepatitis C virus." Bioorganic & Medicinal Chemistry Letters, 2007.
- FDA. "HCV Protease Inhibitors: Approval and Market Status," 2016.
Disclaimer: This is a technical analysis intended for informational purposes; for legal or patent prosecution strategies, consult a qualified patent attorney.
More… ↓
⤷ Start Trial
|
